This is the second quarter of the nine-month period ending Dec.

Alkermes reviews 38 percent of year-over-year income growth from key products Alkermes plc today reported financial results for the one fourth ended Sept. 30, 2013 . This is the second quarter of the nine-month period ending Dec. 31, 2013, as the ongoing company transitions to reporting on a twelve months basis. ‘Against a backdrop of another one fourth of solid financial overall performance, Alkermes is usually advancing one of the most important CNS pipelines in the biopharmaceutical sector,’ commented Richard Pops, CEO of Alkermes. ‘During the one fourth, we achieved crucial milestones for our innovative programs. Excited, 2014 will be an important year for this late-stage pipeline as we obtain stage 3 results for aripiprazole lauroxil and prepare for the NDA submission and start, as well as initiate the phase 3 program for ALKS 5461, which has been granted Fast Monitor status for the adjunctive treatment of major depressive disorder.’ ‘This one fourth's financial results demonstrate the energy of our business design to generate substantial cash flows while also providing the resources to invest in our advancing pipeline,’ commented James Frates, Chief Financial Officer of Alkermes.

Kuppermann. The Iluvien data is particularly noteworthy as it implies that a significant %age of individuals who have the insert encounter long-term eyesight improvement for up to 24 months. In additional AAO annual meeting actions, Alimera will be there at the Tabletop Exhibit at McCormick Place, Lakeside, Level 2, Hall E, during the Retina subspecialty day program, and at booth #4307 on the primary AAO exhibit ground in the South Building, Level 3, Hall A. Alimera is pleased to share information on the Iluvien FAME research at this venue, the most important ophthalmology meeting of the entire year maybe, stated Dan Myers, Alimera president and CEO.